Oxybutynine (Kentera®), nieuwe toedieningsvorm


1. IB-tekst oxybutynine (Kentera®) via: www.cbg-meb.nl, Geneesmiddeleninformatiebank.
2. Davilla GW, et al. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynine treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-145.
3. Dmochowski RR, et al. Comparative efficacy and safety of transdermal oxybutynine and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62: 237-242.
4. CFH-rapport oxybutynine (Kentera®) via: www.cvz.nl, CFH-rapporten. 

Auteurs

  • mw drs M.L.H.A. van Oppenraay, drs D. Bijl